Dr. Kamal Presents at Institute of Women’s Health and Integrative Medicine Conference

Oral and Anal HPV in Women: Understanding Cancer Risk and the Importance of Early Detection

Dr. Mohammad Kamal, CEO of OmniPathology, was honored to present at the Institute of Women’s Health and Integrative Medicine Conference, where he discussed the growing public health concern surrounding oral and anal cancers caused by persistent infection with high-risk types of human papillomavirus (HPV).

During his presentation, Dr. Kamal highlighted the alarming increase in HPV-associated cancers, particularly oropharyngeal (throat) and anal cancers. While HPV is widely recognized as the leading cause of cervical cancer, many patients and healthcare providers remain unaware that the same high-risk HPV types can also contribute to cancers of the throat, anus, and other anatomical sites.

HPV is primarily transmitted through intimate sexual contact. Individuals with multiple lifetime sexual partners, compromised immune systems, a history of HPV infection, or a previous cancer diagnosis may face an elevated risk of developing HPV-associated cancers. Women with a history of cervical HPV infection are also at increased risk for anal cancer due to the close anatomical relationship between the cervical and anal regions. In addition, partners of individuals with HPV infection may be at increased risk for developing oropharyngeal cancer.

A key message of the presentation was the importance of identifying persistent high-risk HPV infections before cancer develops. Persistent infection is one of the strongest known indicators of future cancer risk. Detecting these infections early provides an opportunity for closer clinical monitoring, timely intervention, and referral to appropriate specialists when necessary.

Dr. Kamal emphasized that patients who remain persistently positive for high-risk oropharyngeal HPV should discuss follow-up evaluation with their healthcare provider, which may include assessment by an ear, nose, and throat (ENT) specialist. Early identification of at-risk individuals can help guide surveillance strategies and support improved patient outcomes.

To address the growing need for effective screening and risk assessment, OmniPathology has developed a proprietary, patent-pending oropharyngeal HPV testing program utilizing a simple, non-invasive swab designed to detect 14 high-risk HPV types associated with cancer risk. The test is intended to help clinicians identify patients who may benefit from additional monitoring and specialist evaluation before symptoms appear.

As awareness of HPV-associated cancers continues to expand, advances in testing and early detection are becoming increasingly important tools for healthcare providers. By identifying high-risk infections earlier, clinicians can better stratify patient risk, facilitate appropriate follow-up care, and potentially improve outcomes through earlier intervention.

For additional information about OmniPathology’s oropharyngeal HPV testing program and ordering information, visit OmniOP2.com.